Free Trial

Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma logo
$0.58 +0.10 (+20.28%)
Closing price 04:00 PM Eastern
Extended Trading
$0.58 +0.00 (+0.38%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lyell Immunopharma - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
1
Buy
0

Based on 2 Wall Street analysts who have issued ratings for Lyell Immunopharma in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 2 analysts, 1 has given a sell rating, and 1 has given a hold rating for LYEL.

Consensus Price Target

$1.00
71.88% Upside
According to the 2 analysts' twelve-month price targets for Lyell Immunopharma, the average price target is $1.00. The highest price target for LYEL is $1.00, while the lowest price target for LYEL is $1.00. The average price target represents a forecasted upside of 71.88% from the current price of $0.58.
Get the Latest News and Ratings for LYEL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Lyell Immunopharma and its competitors.

Sign Up

LYEL Analyst Ratings Over Time

TypeCurrent Forecast
3/19/24 to 3/19/25
1 Month Ago
2/18/24 to 2/17/25
3 Months Ago
12/20/23 to 12/19/24
1 Year Ago
3/20/23 to 3/19/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$1.00$1.00$1.00$5.50
Forecasted Upside71.88% Upside63.91% Upside56.01% Upside176.38% Upside
Consensus Rating
Reduce
Reduce
Reduce
Moderate Buy
Remove Ads

LYEL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LYEL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Lyell Immunopharma Stock vs. The Competition

TypeLyell ImmunopharmaMedical CompaniesS&P 500
Consensus Rating Score
1.50
2.82
2.54
Consensus RatingReduceModerate BuyModerate Buy
Predicted Upside70.65% Upside22,993.51% Upside18.14% Upside
News Sentiment Rating
Positive News

See Recent LYEL News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/13/2025HC Wainwright
2 of 5 stars
Mitchell Kapoor
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$1.00 ➝ $1.00+48.92%
10/30/2024Bank of America
4 of 5 stars
 DowngradeBuy ➝ Underperform$6.00 ➝ $1.00+5.47%
8/28/2023JPMorgan Chase & Co.
3 of 5 stars
 DowngradeOverweight ➝ Neutral$15.00 ➝ $5.00+118.34%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 04:33 PM ET.


LYEL Forecast - Frequently Asked Questions

According to the research reports of 2 Wall Street equities research analysts, the average twelve-month stock price forecast for Lyell Immunopharma is $1.00, with a high forecast of $1.00 and a low forecast of $1.00.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lyell Immunopharma in the last twelve months. There is currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" LYEL shares.

According to analysts, Lyell Immunopharma's stock has a predicted upside of 71.88% based on their 12-month stock forecasts.

Lyell Immunopharma has been rated by research analysts at HC Wainwright in the past 90 days.

Analysts like Lyell Immunopharma less than other "medical" companies. The consensus rating for Lyell Immunopharma is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LYEL compares to other companies.


This page (NASDAQ:LYEL) was last updated on 3/19/2025 by MarketBeat.com Staff
From Our Partners